¼¼°èÀÇ ¾Ë·¹¸£±â Áø´Ü ½ÃÀå
Allergy Diagnostics
»óǰÄÚµå : 1526142
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 638 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¾Ë·¹¸£±â Áø´Ü ¼¼°è ½ÃÀåÀº 2030³â±îÁö 83¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2023³â¿¡ 42¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¾Ë·¹¸£±â Áø´Ü ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2023-2030³â¿¡ CAGR 10.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 83¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾Ë·¹¸£±â Áø´Ü ¾î¼¼ÀÌ Å°Æ®´Â º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀ̸ç, CAGRÀº 10.9%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 45¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾Ë·¹¸£±â Áø´Ü ±â±¸ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 10.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 14¾ï ´Þ·¯, Áß±¹Àº CAGR 14.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¾Ë·¹¸£±â Áø´Ü ½ÃÀåÀº 2023³â¿¡ 14¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 11¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2023-2030³â°£ CAGRÀº 14.8%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 7.5%¿Í 9.7%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 9.5%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°è ¾Ë·¹¸£±â Áø´Ü ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

¾Ë·¹¸£±â Áø´Ü¿¡´Â ¾Ë·¹¸£±â ¹ÝÀÀÀ» È®ÀÎÇϰí ÀÌ·¯ÇÑ ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â ƯÁ¤ ¾Ë·¹¸£°ÕÀ» ã¾Æ³»´Â µ¥ »ç¿ëµÇ´Â ´Ù¾çÇÑ °Ë»ç¿Í ÀýÂ÷°¡ Æ÷ÇԵ˴ϴÙ. ¾Ë·¹¸£±â´Â ¸é¿ªÃ¼°è°¡ ²É°¡·ç, À½½Ä, ¹Ý·Áµ¿¹°ÀÇ ºñµë°ú °°Àº À̹°Áú¿¡ ¹ÝÀÀÇÏ¿© ¹ß»ýÇÕ´Ï´Ù. ¾Ë·¹¸£±â Áø´ÜÀÇ ÁÖ¿ä °Ë»ç ¹æ¹ý¿¡´Â ÇǺΠ°Ë»ç, Ç÷¾× °Ë»ç, °úÁ¦ °Ë»ç µîÀÌ ÀÖ½À´Ï´Ù. ÇǺΠÅ×½ºÆ®´Â ÇǺθ¦ ÀáÀçÀû ¾Ë·¹¸£°Õ¿¡ ³ëÃâ½ÃÄÑ ¹ÝÀÀÀ» °üÂûÇÏ´Â °ÍÀ¸·Î, ÇǺΠprick test³ª intradermal test¿Í °°Àº ÇǺΠÅ×½ºÆ®°¡ ´ëÇ¥ÀûÀÔ´Ï´Ù. ¹æ»ç¼º ¾Ë·¹¸£±â ÈíÂø °Ë»ç(RAST)³ª È¿¼Ò °áÇÕ ¸é¿ª ÈíÂø °Ë»ç(ELISA)¿Í °°Àº Ç÷¾× °Ë»ç´Â ¸é¿ª°è°¡ ¾Ë·¹¸£°Õ¿¡ ¹ÝÀÀÇÏ¿© »ý¼ºÇϴ ƯÀÌ Ç×ü(IgE)ÀÇ Á¸À縦 ÃøÁ¤ÇÕ´Ï´Ù. 縰Áö Å×½ºÆ®´Â ÀÇÇÐÀû °ü¸® ÇÏ¿¡ ȯÀÚ¿¡°Ô ¼Ò·®ÀÇ ¾Ë·¹¸£°ÕÀ» Åõ¿©ÇÏ°í ºÎÀÛ¿ëÀ» ¸ð´ÏÅ͸µÇÏ´Â ¹æ½ÄÀ¸·Î ÁøÇàµË´Ï´Ù. ÀÌ·¯ÇÑ Áø´Ü µµ±¸´Â ¾Ë·¹¸£±â¸¦ Á¤È®ÇÏ°Ô Áø´ÜÇϰí ÀûÀýÇÑ °ü¸® ¹× Ä¡·á °èȹÀ» ¼ö¸³ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀ¸·Î ¾Ë·¹¸£±â Áø´ÜÀÇ Á¤È®¼º, È¿À²¼º ¹× ÆíÀǼºÀÌ Å©°Ô Çâ»óµÇ¾ú½À´Ï´Ù. ÃֽŠÁø´Ü ±â¼úÀº ƯÁ¤ ¾Ë·¹¸£°Õ ¼ººÐÀ» °ËÃâÇϴ ÷´Ü ¸é¿ª ÃøÁ¤ ¹× ºÐÀÚÁø´Ü ¹æ¹ýÀ» Ȱ¿ëÇÏ¿© ¾Ë·¹¸£±â ¹Î°¨µµ¿¡ ´ëÇÑ º¸´Ù »ó¼¼ÇÑ ÀÌÇØ¸¦ Á¦°øÇÕ´Ï´Ù. ¸ÖƼÇ÷º½º °Ë»ç Ç÷§ÆûÀº ´ÜÀÏ Ç÷¾× »ùÇÿ¡¼­ ¿©·¯ ¾Ë·¹¸£°ÕÀ» µ¿½Ã¿¡ ºÐ¼®ÇÒ ¼ö ÀÖ¾î Áø´Ü Æò°¡ÀÇ Æ÷°ý¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇöÀå °Ë»ç(point-of-care testing)ÀÇ Çõ½ÅÀº ½Å¼ÓÇÑ ÇöÀå ¾Ë·¹¸£±â Æò°¡¸¦ °¡´ÉÇÏ°Ô Çϰí, Áï°¢ÀûÀÎ °á°ú¸¦ Á¦°øÇÏ¿© Àû½Ã¿¡ ÀÓ»óÀû ÆÇ´ÜÀ» ³»¸± ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ºñħ½ÀÀûÀÌ°í ½Å¼ÓÇÑ Ä¡·á°¡ ¼±È£µÇ´Â ¼Ò¾Æ°ú ¿µ¿ª¿¡¼­ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ÀüÀڰǰ­±â·Ï(EHR) ¹× ¸ð¹ÙÀÏ °Ç°­ ¿ëµµ°ú °°Àº µðÁöÅÐ °Ç°­ µµ±¸ÀÇ ÅëÇÕÀº µ¥ÀÌÅÍ °ü¸®¸¦ °£¼ÒÈ­Çϰí, ȯÀÚ ¸ð´ÏÅ͸µÀ» °³¼±Çϸç, ȯÀÚ¿Í ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü °£ÀÇ ¼ÒÅëÀ» °­È­ÇÔÀ¸·Î½á ¾Ë·¹¸£±â Áø´ÜÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù.

¾Ë·¹¸£±â Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº ¾Ë·¹¸£±â ÁúȯÀÇ À¯º´·ü Áõ°¡, ¾Ë·¹¸£±â °ü¸®¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Áø´Ü ±â¼úÀÇ ¹ßÀü µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. õ½Ä, ¾Ë·¹¸£±â¼º ºñ¿°, À½½Ä¹° ¾Ë·¹¸£±â µî ¾Ë·¹¸£±â ÁúȯÀÇ ¼¼°è ºÎ´ãÀº Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ÁúȯÀ» °ü¸®Çϰí Ä¡·áÇÒ ¼ö ÀÖ´Â È¿°úÀûÀÎ Áø´Ü ¼Ö·ç¼ÇÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¾Ë·¹¸£±â¿¡ ´ëÇÑ »çȸÀû Àνİú ±³À°ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¾Ë·¹¸£±â À¯¹ß ¿äÀÎÀ» ÆÄ¾ÇÇÏ°í °ü¸®ÇÏ·Á´Â °³ÀÎÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Áø´Ü °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±â¼ú Çõ½ÅÀº ¾Ë·¹¸£±â Áø´ÜÀ» º¸´Ù ½±°í Á¤È®ÇÏ°Ô ¸¸µé°í ÀÖÀ¸¸ç, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üµéÀÌ ÀÌ·¯ÇÑ Ã·´Ü µµ±¸¸¦ ÀÓ»ó¿¡ µµÀÔÇϵµ·Ï Àå·ÁÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾Ë·¹¸£±â Ä¡·á ¹× °ü¸®¸¦ °³¼±Çϱâ À§ÇÑ Á¤ºÎ Áö¿øÃ¥°ú ÀÇ·á Á¤Ã¥Àº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ÀÎÇÁ¶óÀÇ È®´ë¿Í ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡µµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼°¡ Áö¼ÓµÇ´Â °¡¿îµ¥, ¾Ë·¹¸£±â Áø´Ü ½ÃÀåÀº Á¤È®Çϰí È¿À²ÀûÀΠȯÀÚ Áß½ÉÀÇ Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¼ö¿ä·Î ÀÎÇØ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÇÕ°è 100°³»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Allergy Diagnostics Market to Reach US$8.3 Billion by 2030

The global market for Allergy Diagnostics estimated at US$4.2 Billion in the year 2023, is expected to reach US$8.3 Billion by 2030, growing at a CAGR of 10.2% over the analysis period 2023-2030. Allergy Diagnostics Assay Kits, one of the segments analyzed in the report, is expected to record a 10.9% CAGR and reach US$4.5 Billion by the end of the analysis period. Growth in the Allergy Diagnostics Instruments segment is estimated at 10.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 14.8% CAGR

The Allergy Diagnostics market in the U.S. is estimated at US$1.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 14.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.5% and 9.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.5% CAGR.

Global Allergy Diagnostics Market - Key Trends & Drivers Summarized

Allergy diagnostics encompasses a range of tests and procedures used to identify allergic reactions and pinpoint specific allergens responsible for these reactions. Allergies occur when the immune system reacts to foreign substances, such as pollen, food, or pet dander, which are typically harmless to most people. The primary methods of allergy diagnostics include skin tests, blood tests, and challenge tests. Skin tests, such as prick tests or intradermal tests, involve exposing the skin to potential allergens and observing the reaction. Blood tests, like the radioallergosorbent test (RAST) and enzyme-linked immunosorbent assay (ELISA), measure the presence of specific antibodies (IgE) that the immune system produces in response to allergens. Challenge tests are conducted under medical supervision and involve introducing small amounts of allergens to the patient and monitoring for adverse reactions. These diagnostic tools are crucial for accurately diagnosing allergies and devising appropriate management and treatment plans.

Technological advancements have significantly improved the accuracy, efficiency, and convenience of allergy diagnostics. Modern diagnostic techniques leverage advanced immunoassays and molecular diagnostics to detect specific allergen components, offering a more detailed understanding of allergic sensitivities. Multiplex testing platforms allow for the simultaneous analysis of multiple allergens from a single blood sample, enhancing the comprehensiveness of diagnostic evaluations. Furthermore, innovations in point-of-care testing enable rapid and on-site allergy assessments, providing immediate results and facilitating timely clinical decisions. These advancements are particularly beneficial in pediatric allergy diagnostics, where non-invasive and quick procedures are preferred. The integration of digital health tools, such as electronic health records (EHRs) and mobile health applications also supports allergy diagnostics by streamlining data management, improving patient monitoring, and enhancing communication between patients and healthcare providers.

The growth in the allergy diagnostics market is driven by several factors, including the increasing prevalence of allergic diseases, rising awareness about allergy management, and advancements in diagnostic technologies. The global burden of allergic conditions, such as asthma, allergic rhinitis, and food allergies, is on the rise, necessitating effective diagnostic solutions to manage and treat these conditions. Growing public awareness and education about allergies have led to higher demand for diagnostic testing, as more individuals seek to identify and manage their allergic triggers. Technological innovations have made allergy diagnostics more accessible and accurate, encouraging healthcare providers to adopt these advanced tools in clinical practice. Additionally, supportive government initiatives and healthcare policies aimed at improving allergy care and management are bolstering market growth. The expansion of healthcare infrastructure and increased investment in research and development further contribute to the market's positive trajectory. As these trends continue, the allergy diagnostics market is poised for significant growth, driven by the ongoing need for precise, efficient, and patient-centric diagnostic solutions.

Select Competitors (Total 100 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â